LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

Aldeyra Therapeutics Inc

Cerrado

6.6 -1.49

Resumen

Variación precio

24h

Actual

Mínimo

6.5

Máximo

6.67

Métricas clave

By Trading Economics

Ingresos

-696K

-16M

BPA

-0.27

Empleados

9

EBITDA

-703K

-15M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+61.09% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

16M

377M

Apertura anterior

8.09

Cierre anterior

6.6

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Aldeyra Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 nov 2024, 20:20 UTC

Principales Movimientos del Mercado

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Comparación entre iguales

Cambio de precio

Aldeyra Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

61.09% repunte

Estimación a 12 meses

Media 10.6 USD  61.09%

Máximo 12 USD

Mínimo 10 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Aldeyra Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.58 / 6.7942Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.